Research

Since their discovery in 2004, the grid cells in the brain, which are important for our orientation, have been regarded as a kind of “GPS in the head.” However, scientists at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now shown that grid cells work much more flexibly than previously assumed. In […]

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma. The Safety Review Committee […]

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today resolved with the approval of the Supervisory Board to implement extensive cost-saving measures and consequently, to focus all development activities exclusively on lead ADC candidate HDP-101 to extend the Company’s cash reach. This […]

The partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases. ZURICH,SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 — VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,“Voyager”), and Secarna Pharmaceuticals GmbH & Co. KG, a company […]

Prestigious award for the developer of the first approved drug against hepatitis D On September 18, Prof. Dr. Dr. h.c. Stephan Urban, DZIF Professor of Translational Virology at Heidelberg University’s Medical Faculty, was honored with the McGuigan Award for Distinguished Work in Drug Discovery. The prize, worth £10,000, recognizes Urban’s outstanding scientific achievement and the […]

A phase 3 clinical trial published in the journal Nature Medicine investigates the benefits of cannabis extract for chronic lower back pain. In the study, which involved over 800 participants and researchers from Heidelberg University’s Medical Faculty, pain was significantly reduced without any serious side effects being observed. Full Text in German below. Cannabisextrakt zur […]

New EMBL research discovers an unexpected relationship between metabolism and cell communication during embryonic development Summary Pregnant women rely on a balanced diet and supplements to deliver proper nutrients to their babies, to ensure they grow healthfully. Such nutrients contribute to fueling development and providing cellular building blocks that lead to healthy brains, bones, organs, […]

Since their discovery in 2004, the grid cells in the brain, which are important for our orientation, have been regarded as a kind of “GPS in the head.” However, scientists at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now shown that grid cells work much more flexibly than previously assumed. In […]

The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by the Hopp Children’s Cancer Center Heidelberg (KiTZ), Jena University Hospital, the German Cancer Research Center (DKFZ), and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks […]